Papillary Thyroid Cancer - Pipeline Review, H1 2016
Global Markets Direct’s, ‘Papillary Thyroid Cancer - Pipeline Review, H1 2016’, provides an overview of the Papillary Thyroid Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer - The report reviews pipeline therapeutics for Papillary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Papillary Thyroid Cancer therapeutics and enlists all their major and minor projects - The report assesses Papillary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Papillary Thyroid Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Papillary Thyroid Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Our reports have been used by over 10K customers, including:
Chondrosarcoma Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Chondrosarcoma Global Clinical Trials Review, H2, 2018" provides an overview of Chondrosarcoma clinical trials scenario.This report provides top line data relating to the clinical trials on Chondrosarcoma. Report...
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 188.8.131.52) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase...
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 220.127.116.11) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies...
Summary Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy.The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer...
Cachexia Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Cachexia Global Clinical Trials Review, H2, 2018" provides an overview of Cachexia clinical trials scenario.This report provides top line data relating to the clinical trials on Cachexia. Report includes...
Bone Metastasis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2018, provides an overview of the Bone Metastasis (Oncology) pipeline landscape. Bone metastasis occurs when cancer cells...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.